Company news

TScan Therapeutics, Inc. news in 2026

TScan Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.

View company

TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

September 2, 2026

TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 12, 2026

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 30, 2026

TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

July 29, 2026

TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

June 24, 2026

TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

June 21, 2026

Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

June 2, 2026

TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

May 5, 2026

TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting

April 27, 2026

TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 8, 2026

TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03

February 25, 2026

TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference

February 25, 2026

Decks in 2026